Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives.

Literature DB >> 25333027

Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives.

Xilin Yang¹, Juliana Cn Chan¹.

Abstract

Entities: Chemical Disease

Year: 2014 PMID： 25333027 PMCID： PMC4200663 DOI： 10.3978/j.issn.2305-5839.2014.06.07

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

20 in total

1. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes.

Authors: Xilin Yang; Wing-Yee So; Ronald C W Ma; Gary T C Ko; Alice P S Kong; Qingsheng Wang; Clive S Cockram; Chun-Chung Chow; Juliana C N Chan; Peter C Y Tong
Journal: Endocr Relat Cancer Date: 2008-06 Impact factor: 5.678

Review 2. Cellular and molecular mechanisms of metformin: an overview.

Authors: Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli
Journal: Clin Sci (Lond) Date: 2012-03 Impact factor: 6.124

3. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.

Authors: Tao Zhang; Xinyang Wang; Dalin He; Xunbo Jin; Peng Guo
Journal: Anticancer Drugs Date: 2014-09 Impact factor: 2.248

4. Fasting serum glucose level and cancer risk in Korean men and women.

Authors: Sun Ha Jee; Heechoul Ohrr; Jae Woong Sull; Ji Eun Yun; Min Ji; Jonathan M Samet
Journal: JAMA Date: 2005-01-12 Impact factor: 56.272

5. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.

Authors: Chen Qu; Weijia Zhang; Guopei Zheng; Zijuan Zhang; Jiang Yin; Zhimin He
Journal: Mol Cell Biochem Date: 2013-10-06 Impact factor: 3.396

6. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

Authors: Xilin Yang; Gary T C Ko; Wing Yee So; Ronald C W Ma; Linda W L Yu; Alice P S Kong; Hailu Zhao; Chun-Chung Chow; Peter C Y Tong; Juliana C N Chan
Journal: Diabetes Date: 2010-02-25 Impact factor: 9.461

7. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.

Authors: James Sinnett-Smith; Krisztina Kisfalvi; Robert Kui; Enrique Rozengurt
Journal: Biochem Biophys Res Commun Date: 2012-11-15 Impact factor: 3.575

8. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.

Authors: Xiaona Liu; Rishi Raj Chhipa; Shabnam Pooya; Matthew Wortman; Sara Yachyshin; Lionel M L Chow; Ashish Kumar; Xuan Zhou; Ying Sun; Brian Quinn; Christopher McPherson; Ronald E Warnick; Ady Kendler; Shailendra Giri; Jeroen Poels; Koenraad Norga; Benoit Viollet; Gregory A Grabowski; Biplab Dasgupta
Journal: Proc Natl Acad Sci U S A Date: 2014-01-13 Impact factor: 11.205

Review 9. Metformin and the risk of cancer: time-related biases in observational studies.

Authors: Samy Suissa; Laurent Azoulay
Journal: Diabetes Care Date: 2012-12 Impact factor: 19.112

10. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.

Authors: Alice P S Kong; Xilin Yang; Wing-Yee So; Andrea Luk; Ronald C W Ma; Risa Ozaki; Kitty K T Cheung; Heung-Man Lee; Linda Yu; Gang Xu; Chun-Chung Chow; Juliana C N Chan
Journal: BMC Med Date: 2014-05-13 Impact factor: 8.775

3 in total